Joe Zakrzewski

Is Amarin's (NASDAQ: AMRN) Vascepa the victim of its own ineptitude, or the target of an effort by Big Pharma to keep it off the market? Those questions and others have been lobbed around lately by a variety of industry observers and investors, regarding Amarin's sole product, Vascepa – a...

Trading in shares of Amarin (NASDAQ: AMRN) has been muted on Friday despite the expectation for high levels of volatility after the stock plunged 20 percent in Thursday's after hours trading session. It would appear that the stock has found equilibrium after the big after hours decline, because...

Shares of biotech firm Amarin (NASDAQ: AMRN) were crushed in after hours trading on Thursday after the company announced plans to raise $100 million in debt financing and to hire 250-300 sales reps to market its fish-oil drug Vascepa. The stock finished the after hours session down more than 18...